{"id":963154,"date":"2026-05-14T16:44:11","date_gmt":"2026-05-14T20:44:11","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/innovate-corp-announces-first-quarter-2026-results\/"},"modified":"2026-05-14T16:44:11","modified_gmt":"2026-05-14T20:44:11","slug":"innovate-corp-announces-first-quarter-2026-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/innovate-corp-announces-first-quarter-2026-results\/","title":{"rendered":"INNOVATE Corp. Announces First Quarter 2026 Results"},"content":{"rendered":"
\n

\n – Infrastructure: Strong first quarter results with revenue of\u00a0<\/em>
\n $357.9 million<\/em>
\n
\n – Life Sciences: MediBeacon receives the CE <\/em>
\n mark<\/em>
\n for the Transdermal GFR Monitor and Reusable Sensor<\/em>
\n
\n – Spectrum: More than 60 new license applications filed to expand national footprint and increase population coverage<\/em>\n <\/p>\n

NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) — INNOVATE Corp. (\u201cINNOVATE\u201d or the \u201cCompany\u201d) (NYSE: VATE) announced today its consolidated results for the first quarter.<\/p>\n

\n Financial Summary<\/strong>\n <\/p>\n\n\n\n\n\n\n\n\n\n
(in millions, except per share amounts)<\/td>\n\n Three Months Ended March 31,<\/strong>\n <\/td>\n<\/tr>\n
\u00a0<\/td>\n\n 2026<\/strong>
\n \n <\/td>\n		\u00a0<\/td>\n\n 2025<\/strong>
\n \n <\/td>\n		\u00a0<\/td>\n\n Increase \/ (Decrease)<\/strong>\n <\/td>\n<\/tr>\n
Revenue<\/td>\n$<\/td>\n364.8<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n274.2<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n33.0<\/td>\n%<\/td>\n<\/tr>\n
Net loss attributable to common stockholders and participating preferred stockholders<\/td>\n$<\/td>\n(17.2<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n(24.8<\/td>\n)<\/td>\n\u00a0<\/td>\n30.6<\/td>\n%<\/td>\n<\/tr>\n
Basic and Diluted loss per share attributable to common stockholders<\/td>\n$<\/td>\n(1.29<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n(1.89<\/td>\n)<\/td>\n\u00a0<\/td>\n31.7<\/td>\n%<\/td>\n<\/tr>\n
Total Adjusted EBITDA(1)<\/sup><\/td>\n$<\/td>\n19.7<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n7.2<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n173.6<\/td>\n%<\/td>\n<\/tr>\n
(1) Reconciliation of GAAP to Non-GAAP measures follows<\/td>\n<\/tr>\n
\u00a0<\/td>\n<\/tr>\n<\/table>\n

\n Commentary<\/strong>\n <\/p>\n

“INNOVATE delivered a strong start to the year, with solid execution and improving visibility across the portfolio,\u201d said Avie Glazer, Chairman of INNOVATE. \u201cInfrastructure performed well in the first quarter, supported by healthy sales performance, strong backlog and pipeline, and continued opportunities in the technology-related construction markets that are concentrated around AI infrastructure, energy systems, advanced manufacturing, and digital connectivity. In Life Sciences, MediBeacon received CE mark approval for the Transdermal GFR Monitor and Reusable Sensor in Europe, while R2 continued to expand internationally. We also made progress in Spectrum through successful collaborative trials, supporting potential market launches in the second half of 2026.”<\/p>\n

“We continue to advance our strategic priorities and strengthen the foundation of the Company,\u201d said Paul Voigt, Interim CEO of INNOVATE. \u201cDBM Global exited the quarter with strong momentum, supported by a robust pipeline and early progress building 2027 backlog, reinforcing confidence in sustained revenue and potential upside. In Life Sciences, MediBeacon achieved key regulatory and commercial milestones, including CE Mark approval of the Transdermal GFR Monitor and Reusable Sensor in Europe and growing momentum with key academic medical centers, while R2 continued to expand internationally. At Spectrum, despite near\u2011term advertising pressures, we are encouraged by progress on strategic opportunities that position the business for improved performance in 2026.”<\/p>\n

\n First Quarter 2026 and Recent Highlights<\/strong>\n <\/p>\n

\n
\n Infrastructure<\/u>
\n <\/strong>\n <\/p>\n